Scancell Holdings
SCLP · AIM · Health Care · mcap £129m · 9.3p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | Results | Final Results
Preliminary Results for the year ended 30 April 2026 |
−1.1% |
| 02 Oct 26 | Notice of GM
Scancell Holdings plc (AIM: SCLP) ("Scancell", or the "Company"), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat canc |
+1.6% | |
| 24 Sep 26 | Scancell completes up to US$25m in debt financing
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development |
−1.0% | |
| 03 Sep 26 | Scancell to Present at the H.C. Wainwright Sept 26
Scancell Holdings plc (AIM: SCLP), a late-stage clinical immuno-oncology company developing active immunotherapies designed to enhance anti-tumor immune responses in difficult-to-treat cancers, announced today that compa |
−0.5% | |
| 19 Aug 26 | ISCIB1+ MHRA CTA Approval for Ph3 trial
Scancell Receives UK MHRA Clinical Trial Authorization for the Phase 3 Registrational Trial of iSCIB1+ in Advanced Melanoma |
+1.1% | |
| 06 Aug 26 | Holding | Holding(s) in Company | |
| 31 Jul 26 | Holding | Holding(s) in Company | |
| 31 Jul 26 | Extension of Option Exercise Period
Extension of exercise period for CSO share options |
−0.5% | |
| 28 Jul 26 | Holding | Holding(s) in Company | |
| 27 Jul 26 | Fundraise | Result of Retail Offer and Total Voting Rights
Result of Oversubscribed Retail Offer and Total Voting Rights |
+2.6% |
| 24 Jul 26 | Merger and Financing
The following amendments have been made to the 'Merger and Financing' announcement released on 23 July 2026 at 08:05:45 under RNS No 5640N. |
−10.5% | |
| 23 Jul 26 | Fundraise | Oversubscribed UK Placing
596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). |
−17.6% |
| 23 Jul 26 | Merger and Financing
596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). |
−17.6% | |
| 23 Jul 26 | Fundraise | Launch of Retail Offer
Retail Offer to raise up to £2.3 million (c.$3.0 million) |
−17.6% |
| 23 Jul 26 | Fundraise | Proposed UK Placing
596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). |
−17.6% |
| 26 Jun 26 | Response to Press Speculation
Scancell Holdings plc (AIM: SCLP) ("Scancell" or the "Company"), the developer of active immunotherapies to treat cancer, notes recent press speculation and confirms it is in advanced discussions with Neuphoria Therapeut |
−3.2% | |
| 28 Apr 26 | FDA Fast Track Designation for iSCIB1+
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study |
+5.8% | |
| 02 Apr 26 | Board change | CFO transition
David Schilansky to be appointed as financial advisor and interim CFO, bringing extensive industry and financial experience, including leading IPOs on Nasdaq and Euronext |
+0.0% |
| 29 Jan 26 | Results | Half-year Results
Interim Results for the six months ended 31 October 2025 |
−2.8% |
| 26 Jan 26 | FDA clearance of IND application for iSCIB1+
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma |
+1.3% | |
| 22 Jan 26 | Routine | Notice of Results | |
| 09 Dec 25 | Continued improvement in PFS with iSCIB1+
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma |
−4.4% | |
| 07 Nov 25 | Research Update
Scancell holds oral presentation of positive Phase 2 data on Immunobody® iSCIB1+ in late-stage melanoma at SITC 2025 |
+1.5% | |
| 30 Oct 25 | Routine | Result of AGM |
Company filings. Not investment advice.